CA
NZ
UK
AU
IND
US
Processa Pharmaceuticals (NASDAQ:PCSA) is a clinical-stage biopharmaceutical company developing what it calls Next Generation Cancer therapies. Its approach modifies existing FDA-approved oncology drugs to alter how they are metabolized and distributed in the body while aiming to preserve their cancer-killing activity.
Pyxis Oncology (NASDAQ:PYXS) is a clinical-stage biotechnology company developing therapeutics for solid tumors, with a focus on antibody-drug conjugates (ADCs), targeted therapies that deliver a cytotoxic payload to cancer cells. Its lead candidate, MICVO (micvotabart pelidotin), is in early-phase trials for head and neck …
MBX Biosciences (NASDAQ:MBX) is a pre-commercial biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders. Its pipeline spans hypoparathyroidism and obesity, areas with substantial unmet need and investor interest.
Anixa Biosciences (NASDAQ:ANIX) is a clinical-stage biotechnology company developing therapies and vaccines addressing cancer. Its programs include a breast-cancer vaccine developed in collaboration with a major medical institution and a CAR-T cell therapy for ovarian cancer, among other immunotherapy efforts.
Advanced Biomed (NASDAQ:ADVB) began as a life-sciences business but has been actively reshaping itself into an artificial-intelligence-focused company. That transition has been pursued through acquisitions, leadership change and the divestiture of legacy operations.
This figure marks a notable 10.2% increase from the same period last year, surpassing consensus estimates for earnings per share (EPS) which landed at $3.12 compared to an anticipated $2.85. The impressive performance highlights the firm's strong operational execution and demand for its diagnostic …
Eli Lilly is positioning itself for a significant leap in the obesity treatment market through its planned submission for the FDA approval of retatrutide in 2027. This next-generation obesity drug has successfully passed two additional Phase 3 trials, expanding its clinical validation after five …
The move comes as the company seeks to translate its silicon nitride platform into commercially viable medical‑technology offerings, aiming to strengthen its position within the broader med‑tech environment.
Thermo Fisher Scientific achieved revenue growth of 10% to $11.99 billion in its latest quarterly results, exceeding market expectations. The company’s adjusted EPS increased by 13% to $6.03, signaling strong performance and strategic momentum in the healthcare sector.Key HighlightsSecond quarter revenue climbed to $11.99 …
West Pharmaceutical Services has reported its second-quarter earnings for the fiscal year, showcasing a significant uptick in financial performance. The company's earnings per share hit $2.13, surpassing analysts' expectations. This remarkable figure highlights the strong demand for West's products and services, particularly in the …
Please wait processing your request...